LGALS13

Across TCGA pan-cancer cohorts, LGALS13 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated LGALS13 data layer compared with 4 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher LGALS13 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LGALS13 expression acts as an unfavorable survival marker, although some lineages such as THCA show a favorable association.

MESO, READ, and BLCA are the cancer types where LGALS13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Tertile	III,IV	0.069	0.422	<.001	54	view →
READ	DFS	Tertile	III,IV	0.027	0.761	<.001	54	view →
BLCA	DFS	Tertile	All	0.117	0.604	<.001	54	view →
THYM	OS	Tertile	All	0.476	0.943	<.001	39	view →
UCS	DFS	Tertile	IV	0.132	0.718	.002	36	view →
UVM	OS	Tertile	All	0.220	0.917	<.001	27	view →
PCPG	DFS	Tertile	All	0.530	0.898	<.001	27	view →
ACC	OS	Tertile	III,IV	0.338	0.719	.038	21	view →
GBM	OS	Tertile	All	0.275	0.428	.044	18	view →
LUAD	DFS	Tertile	IV	0.342	0.893	<.001	18	view →
DLBC	OS	Tertile	II,III,IV	0.118	0.802	.025	18	view →
LUSC	OS	Tertile	II,III,IV	0.239	0.618	.011	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

LGALS13–MESO (DFS)

Open the MESO breakdown →